Cannabidiol (CBD) Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cannabidiol (CBD) Market Trends and Insights

Chronic Pain Management Driving Prescription CBD Uptake

Prescription adoption is climbing as CBD proves effective for refractory neurological disorders. Jazz Pharmaceuticals reported 46-87% median seizure reductions in multiple epilepsy types, and 89% of caregivers intend to continue Epidiolex therapy. Nurses documented seizure declines in 85% of treated cases, and behavioral improvements were observed in patients with tuberous sclerosis complex. These outcomes necessitate broader clinical trials for chronic pain, prompting pharmaceutical investment in cannabinoid research and development. United States rescheduling to Schedule III would facilitate FDA approval and pharmacy distribution, thereby expanding reimbursable access in the cannabidiol market.

Regulatory Pathways Opening for Over-the-Counter CBD in Pharmacy Chains

Japan’s December 2024 Cannabis Control Law revision permits medical cannabis products and introduces a tiered cultivation license, ending a decades-long “drug lag”.^{[1]GR Japan, “Cannabis Law Reform Summary,” grjapan.com}In the United States, the FDA acknowledges that present supplement rules cannot govern CBD, prompting legislative proposals while states enact divergent measures, such as California’s emergency ban on hemp foods with detectable THC.^{[2]FDA, “Cannabidiol Product Safety Update,” fda.gov}Mainstream pharmacy groups are therefore preparing OTC shelves for compliant SKUs once federal clarity emerges, expanding the cannabidiol market.

Adoption of CBD-Infused Functional Foods Among Aged Population

Older consumers seek non-pharmaceutical relief for sleep, joint, and inflammatory issues, accelerating demand for functional foods fortified with cannabidiol. Le Herbe’s water-dissolvable powder leverages nanoemulsion to reduce onset to 15–30 minutes and triple shelf life. 3-D-printed tablets allow bespoke dosages, albeit at printer costs above USD 4,000 that limit near-term scaling. Enhanced bioavailability positions CBD beverages and snacks as routine dietary aids with further growth opportunities for the cannabidiol market.

Increasing Awareness among Consumers Regarding Health

Convenience-store surveys show that the majority of shoppers recognize the benefits of CBD, even though trial rates lag. Education campaigns stress correct dosage and COA verification, a strategy reinforced by Tilray’s hemp-derived delta-9 THC beverage roll-out as an alcohol alternative across large developed markets. National beverage chains stocking THC seltzers underscore the normalization of cannabinoid consumption within the expanding cannabidiol market.

Strict Regulation on Cannabidiol Products

Japan enforces the world’s lowest THC threshold, demanding zero-detectable levels in imported CBD and limiting raw material to mature stalk and seed, thereby tightening supply channels.^{[3]USDA FAS, “Japan Hemp Market Report,” usda.gov}In the United States, FDA’s stance that current supplement rules are “inadequate” sustains a federal vacuum, while California bans retail hemp foods with detectable THC. Unaligned rules raise compliance costs and delay nationwide rollouts.

Price Compression from Oversupply of Hemp Biomass

Hemp acreage planted boom still feeds inventories, forcing isolate prices downward and cutting brand counts from 4,000 to roughly 2,000. Charlotte’s Web responded by debuting CBN-led “Stay Asleep” gummies to capture premium sleep-aid demand. Ultrasonic and pressurized-liquid extraction allow purity gains that justify higher margins, yet processors without IP or scale exit the CBD market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Source: Hemp Commands Volume While Marijuana Gains Value Momentum

Hemp-derived products captured 55.12% of 2025 revenue as favorable legislation and established farming supply chains ensured consistent input quality. The CBD market size for hemp formats is projected to expand at a mid-teens CAGR as ingestibles and cosmetics widen consumer reach. Demand for marijuana-derived extracts, however, is forecast to climb 18.35% annually between 2026 and 2031 as the entourage effect gains clinical backing and potential U.S. Schedule III status relaxes research barriers. The CBD market welcomes hybrid extraction methods such as Smokenol that capture smoke-borne terpenes, blurring traditional source distinctions and enabling tailored cannabinoid ratios for formulators.

Hemp’s legal clarity supports multinational retailers that require THC-free inventory, especially in Europe and parts of Asia. Marijuana-sourced CBD appeals to prescription channels where trace THC content is permissible under pharmacopoeia standards. As pharmaceutical trials broaden beyond epilepsy to pain and anxiety, vertically integrated cultivators with both hemp and marijuana licenses are best positioned to supply diversified APIs at scale.

By End Use: Pharmaceuticals Lead Revenue; Pet Care Races Ahead

Pharmaceutical applications generated 40.91% of 2025 sales, buoyed by Epidiolex’s USD 198.7 million Q1 2024 revenue and continued expansion into tuberous sclerosis and Lennox-Gastaut syndrome indications. This dominance translates into the highest CBD market share across end uses, with payers increasingly reimbursing cannabinoid prescriptions. The CBD market size for pet care, however, is forecast to advance at 31.28% CAGR as owners adopt functional chews and oils for arthritis, anxiety, and postoperative recovery in companion animals. Veterinary practitioners cite growing peer-reviewed evidence for canine osteoarthritis pain reduction, underpinning demand for GMP-grade tinctures.

Wellness and personal-use SKUs continue evolving toward targeted benefits. “Stay Asleep” CBN plus CBD gummies address the 67% of adults reporting sleep issues, illustrating how broadened cannabinoid profiles capture additional consumer need states. Such functional diversification boosts category resiliency against raw-material oversupply shocks.

By Product Form: Oils & Tinctures Retain Pole Position While Gummies Surge

Consumers gravitate toward oils and tinctures for dosage flexibility, granting the format 37.48% revenue in 2025. Precise droppers and minimal excipients appeal to medically supervised regimens, sustaining trust among health-care providers. Gummies and confectionery, projected to grow 29.35% annually to 2031, attract first-time users who prefer familiar snack formats and tastemasked profiles. Alcohol-replacement trends further energize the CBD market size for gummies; Australian consumers cite cannabis gummies’ hangover-free benefit when choosing them over beer.

Advanced nanoemulsion shortens edible onset to under 30 minutes and boosts bioavailability, eroding oils’ speed advantage and expanding gummies’ evening-winding-down occasions. Topicals are likewise adopting water-soluble nano-drops to lift dermal absorption, underpinning the premiumization of cosmetic SKUs.

By Distribution Channel: Brick-and-Mortar Still Commands Trust; E-Commerce Accelerates

Retail stores accounted for 46.02% of 2025 revenue, as shoppers value live staff guidance and instant product access. Pharmacies, wellness chains, and grocery banners broaden shelf space following clearer local statutes. Nonetheless, E-commerce is on a 21.86% CAGR trajectory. In the CBD market, patients dealing with chronic conditions often prefer one-click reordering and discreet delivery options to avoid stigma and maintain privacy.

Convenience retailers like Circle K expand pilot kiosks stocked with broad-spectrum gummies and seltzers, while Yesway’s Feel Good Shop+ curates impulse-purchase SKUs adjacent to energy drinks. Potential U.S. Schedule III rescheduling would channel FDA-approved cannabinoid drugs into hospital and specialty pharmacies, cementing medical supply chains that align with payer reimbursement and physician prescribing workflows.

Geography Analysis

North America remained the epicenter of the CBD market with 46.55% revenue in 2025. Imminent federal rescheduling is expected to shrink illicit channels, reduce possession arrests, and catalyze double-digit investment in clinical trials. Consolidation is also reshaping the landscape; Cresco Labs’ USD 2 billion acquisition of Columbia Care exemplifies scale pursuit under tightening capital markets. Canada remains the hub for GMP-grade cannabinoid research, while Mexico’s pending secondary regulations could open Latin America’s most populous market.

Asia-Pacific is projected to post a 19.74% CAGR through 2031, propelled by Japan’s landmark reforms that legalize medical cannabinoid products. China’s beauty sector leads CBD adoption via cross-border e-commerce, with luxury serums commanding premium pricing. Australia’s Special Access Scheme facilitates prescription CBD for anxiety and insomnia, building physician familiarity and patient loyalty.

Europe presents sizable upside as Germany moves to decriminalize adult-use cannabis, lifting investor sentiment and reviving Canopy Growth’s European restructuring. The European Monitoring Centre for Drugs and Drug Addiction is drafting a harmonized CBD safety framework, addressing current patchworks that hamper trade. The UK emphasizes novel-food authorizations, fostering white-label supply chains. France and Italy accelerate medical-cannabis trials, stimulating pharmaceutical demand for GMP isolate and distillate.

Regulatory Landscape

Regulation continues to split between pharmaceutical and consumer pathways. In the United States, the FDA maintains that CBD cannot be marketed as a dietary supplement or added to food under the current statutory framework, while enforcement activity continues through warning letters and postmarket monitoring. In April 2026, the FDA also outlined limited enforcement-discretion conditions tied to physician-directed furnishing for certain hemp-derived CBD products within Medicare-linked contexts. On the controlled-substances side, an April 2026 Federal Register rule clarified the DEA Administrator's scheduling authority for FDA-approved drug products containing marijuana (or marijuana components), reinforcing an established compliance route for approved cannabinoid pharmaceuticals.

In Europe, CBD ingestibles face a high evidentiary bar under the Novel Food regime. In February 2026, the European Commission issued Implementing Decision C(2026) 683, terminating an authorization procedure for CBD from Cannabis sativa L. as a novel food without adding it to the Union list. EFSA, in February 2026, set a provisional safe intake level for CBD in novel food formulations (0.0275 mg/kg body weight per day), and in May 2026 published an opinion stating that safety for a specific CBD isolate novel food could not be established due to data gaps. For medicines, the EMA continues to manage cannabinoid product development through established procedures, including a January 2025 decision modifying the agreed paediatric investigation plan for Epidyolex (cannabidiol).

Market Opportunities and Future Outlook

Pharmaceutical-grade CBD market access is expanding through clearer, country-specific authorization pathways and drug-development milestones. In the United States, April 2026 actions combined a controlled-substances compliance clarification for FDA-approved marijuana-derived drug products (Schedule III handling for approved products) with an FDA enforcement-discretion posture that is narrower and more clinical in nature. That combination creates room for compliant CBD offerings that align more closely with healthcare delivery than general retail supplementation. In Brazil, ANVISA published Resolution RDC No. 1.015 in February 2026 (effective May 4, 2026), establishing requirements for manufacturing, importing, and commercializing CBD or Cannabis sativa L. extract products for human medicinal use, and defining a route for registered operators and contract manufacturers serving the regulated medical channel.

Product and supply-chain differentiation is shifting away from commodity tinctures toward regulated formulations, novel delivery approaches, and alternative inputs. A notable proof point is India, where Zenara Pharma received CDSCO approval in July 2026 for a 150 mg/mL synthetic CBD oral solution for mild-to-moderate anxiety, developed with Leiutis Pharmaceuticals LLP. The approval highlights a pathway that bypasses botanical THC-threshold variability and can fit conventional pharmaceutical quality systems. At the same time, EU novel-food scrutiny and EFSA safety data requirements are tightening near-term whitespace toward topical cosmetics in permissive jurisdictions and toward prescription or medically supervised use cases globally, leaving brands with defensible IP (bioavailability technologies, validated COAs, and GMP-grade supply) with stronger positioning in pharmacy and reimbursable ecosystems compared with general wellness SKUs.